What You Should Know:
– Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira Precision Health Inc.
– This collaboration aims to advance OCB’s proprietary ToxNav® test in the United States, a revolutionary precision oncology tool designed to identify patients at high risk of severe toxicity from common chemotherapy treatments.
– Mira Precision Health, headquartered at the Mason 5155 BioHub in Mason, Ohio, is dedicated to advancing precision medicine by delivering innovative solutions that empower clinics, health systems, and independent providers. Together, OCB and Mira Precision Health will work to establish a substantial future market and sales presence for ToxNav® in the U.S..
Revolutionizing Cancer Drug Safety with ToxNav®
The ToxNav® test identifies cancer patients who have a high likelihood of experiencing extreme toxicity when treated with 5FU/capecitabine, some of the most widely used cancer drugs globally. In severe cases, this toxicity can be fatal.
The ToxNav® test enhances clinical decision-making through comprehensive genetic profiling and directly aligns with recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines, which recommend DPYD testing for colorectal cancer patients receiving fluoropyrimidine-based treatments.
Dr. David Kerr, Founder and Director of the Board of OCB, and Professor of Cancer Medicine at Oxford University, commented, “We developed our ToxNav test to identify cancer patients that have a high likelihood of undergoing extreme toxicity to 5FU/capecitabine treatment, which is one of the most widely used cancer drugs in the world. We have already clinically proven that ToxNav identifies patients that are susceptible to extreme toxicity and are excited to have partnered the test with Mira Precision, who have complementary expertise to advance ToxNav in the USA. We look forward to a long and productive relationship with Mira Precision as we advance ToxNav to widen its clinical utility in the USA and save more patient lives”.
